10-QPeriod: Q1 FY2005

QUEST DIAGNOSTICS INC Quarterly Report for Q1 Ended Mar 31, 2005

Filed April 29, 2005For Securities:DGX

Summary

Quest Diagnostics Inc. reported solid financial performance for the first quarter of 2005, with net revenues increasing by 5.1% to $1.32 billion compared to the same period in 2004. This growth was driven by a 2.8% increase in testing volumes and a 2.3% rise in average revenue per requisition, attributed to a shift towards higher-value and gene-based testing, alongside modest price increases. Net income rose to $131.6 million ($1.28 diluted EPS) from $116.1 million ($1.08 diluted EPS) in the prior year's first quarter. The company also demonstrated effective cost management, with selling, general, and administrative expenses decreasing as a percentage of net revenues, benefiting from revenue growth and operational efficiencies from Six Sigma initiatives. Investments were made in sales, service, science, and IT, which are expected to further differentiate the company and improve cost structures. The company continued its share repurchase program and increased its quarterly dividend, signaling confidence in its financial stability and future prospects.

Key Highlights

  • 1Net revenues increased by 5.1% to $1.32 billion for the three months ended March 31, 2005, compared to $1.26 billion in the prior year.
  • 2Net income grew by 13.3% to $131.6 million, with diluted earnings per share (EPS) rising to $1.28 from $1.08 year-over-year.
  • 3Testing volumes increased by 2.8%, and average revenue per requisition grew by 2.3%, indicating a favorable shift in test mix towards higher-value services.
  • 4Cost of services as a percentage of net revenues slightly increased to 59.1% due to investments in supplies and infrastructure, partially offset by efficiency gains.
  • 5Selling, general, and administrative expenses as a percentage of net revenues decreased to 23.4% from 24.5%, driven by revenue leverage and efficiency initiatives.
  • 6The company continued its share repurchase program, buying back $62.3 million of its common stock in the quarter, and increased its quarterly dividend to $0.18 per share.
  • 7Quest Diagnostics completed the redemption of its contingent convertible debentures in January 2005, reducing future interest expenses.

Frequently Asked Questions

Revenue growth was driven by a combination of increased testing volumes, which rose by 2.8%, and an improvement in average revenue per requisition by 2.3%. The latter was influenced by a shift towards higher-value tests, including gene-based testing, and an increase in the number of tests ordered per requisition.

The company focused on operational efficiencies through its Six Sigma and standardization initiatives. While cost of services saw a slight increase as a percentage of revenue due to investments in supplies and infrastructure, selling, general, and administrative expenses decreased as a percentage of revenue, benefiting from revenue growth and improved collection processes.

Quest Diagnostics anticipates investing approximately $210 million to $230 million in capital expenditures for 2005, primarily in information technology, equipment, and facility upgrades. The company believes that cash from operations and its existing credit facilities will provide sufficient financial flexibility to fund these investments, debt service, dividends, share repurchases, and future growth opportunities.

During the first quarter of 2005, Quest Diagnostics completed the redemption of its contingent convertible debentures. The company also repaid $100 million of its senior unsecured revolving credit facility by utilizing borrowings under its secured receivables credit facility. Additionally, $62.3 million was spent on treasury stock repurchases, and the quarterly dividend was increased.